BioLineRx (BLRX) Research & Development (2023 - 2025)
Historic Research & Development for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.7 million.
- BioLineRx's Research & Development rose 3298.25% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year increase of 2746.97%. This contributed to the annual value of -$9.1 million for FY2024, which is 2691.91% up from last year.
- Latest data reveals that BioLineRx reported Research & Development of -$1.7 million as of Q3 2025, which was up 3298.25% from -$2.3 million recorded in Q2 2025.
- In the past 5 years, BioLineRx's Research & Development ranged from a high of -$1.6 million in Q1 2025 and a low of -$3.7 million during Q1 2023
- Its 3-year average for Research & Development is -$2.5 million, with a median of -$2.5 million in 2024.
- As far as peak fluctuations go, BioLineRx's Research & Development skyrocketed by 3987.75% in 2024, and later tumbled by 453.93% in 2025.
- Over the past 3 years, BioLineRx's Research & Development (Quarter) stood at -$3.1 million in 2023, then surged by 39.88% to -$1.9 million in 2024, then grew by 7.83% to -$1.7 million in 2025.
- Its Research & Development was -$1.7 million in Q3 2025, compared to -$2.3 million in Q2 2025 and -$1.6 million in Q1 2025.